Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias.
Plasma cell dyscrasias (PCD) are due to an abnormal proliferation of a single clone of plasma or lymphoplasmacytic cells leading to secretion of immunoglobulin (Ig) or an Ig fragment, causing the dysfunction of multiple organs. Median survival of these patients has significantly improved over the last decade due to availability of treatment options such as high-dose melphalan with autologous stem cell transplantation and novel anti-myeloma agents. Renal transplantation has not traditionally been considered in these patients due to the previously limited prognosis, along with concerns relating to disease recurrence affecting the renal allograft and increased infection susceptibility following renal transplant due to immunosuppression and the PCD itself. However, with the increasing range of effective treatment options, renal transplantation could now be considered, especially in young patients with good performance status. It is therefore timely to reappraise the potential role of renal transplantation in end-stage renal disease due to multiple myeloma and other PCD. This review summarizes the literature relating to renal transplantation in PCD, including multiple myeloma, monoclonal Ig deposition disease and systemic AL amyloidosis, to attempt to identify patients who may benefit most from this approach and to explore areas for further development.
Sheffield Kidney Institute, Sheffield, UK.
Tarun
T
Bansal
Anshu
A
Garg
John A
JA
Snowden
William
W
McKane
D006801:Humans; D016030:Kidney Transplantation; D009101:Multiple Myeloma / Q000601:surgery*; D010265:Paraproteinemias / Q000601:surgery*; D018579:Patient Selection; D011379:Prognosis